Literature DB >> 31363908

Tumor recurrence patterns after surgical resection of intracranial low-grade gliomas.

Yasukazu Fukuya1, Soko Ikuta1, Takashi Maruyama1,2, Masayuki Nitta1,2, Taiichi Saito2, Shunsuke Tsuzuki2, Mikhail Chernov1, Takakazu Kawamata2, Yoshihiro Muragaki3,4.   

Abstract

INTRODUCTION: Tumor recurrence patterns after resection of intracranial low-grade gliomas (LGG) generally remain obscured. The objective of the present retrospective study was their multifaceted analysis, evaluation of associated factors, and assessment of impact on prognosis.
METHODS: Study group comprised 81 consecutive adult patients (46 men and 35 women; median age, 37 years) with recurrent diffuse astrocytomas (DA; 51 cases) and oligodendrogliomas (OD; 30 cases). The median length of follow-up after primary surgery was 6.7 years.
RESULTS: Early (within 2 years after primary surgery) and non-early (> 2 years after primary surgery) recurrence was noted in 23 (28%) and 58 (72%) cases, respectively. Fast (≤ 6 months) and slow ( > 6 months) radiological progression of relapse was noted in 31 (38%) and 48 (59%) cases, respectively. Tumor recurrence was local and non-local in 71 (88%) and 10 (12%) cases, respectively. Recurrence patterns have differed in OD, IDH1-mutant DA, and IDH wild-type DA. Early onset, fast radiological progression, and non-local site of relapse had statistically significant negative impact on overall survival of patients and were often associated with malignant transformation of the tumor (38 cases). However, in subgroup with extent of resection ≥ 90% (56 cases) no differences in recurrence characteristics were found between 3 molecularly defined groups of LGG.
CONCLUSIONS: Recurrence patterns after resection of LGG show significant variability, differ in distinct molecularly defined types of tumors, and demonstrate definitive impact on prognosis. Aggressive resection at the time of primary surgery may result in more favorable characteristics of recurrence at the time of its development.

Entities:  

Keywords:  Adjuvant therapy; Fractionated radiotherapy; Low-grade glioma; Recurrence; Surgery; Survival

Mesh:

Year:  2019        PMID: 31363908     DOI: 10.1007/s11060-019-03250-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  16 in total

Review 1.  Repeated Awake Surgical Resection(s) for Recurrent Diffuse Low-Grade Gliomas: Why, When, and How to Reoperate?

Authors:  Hugues Duffau
Journal:  Front Oncol       Date:  2022-07-05       Impact factor: 5.738

Review 2.  Surgical Neuro-Oncology: Management of Glioma.

Authors:  Dana Mitchell; Jack M Shireman; Mahua Dey
Journal:  Neurol Clin       Date:  2022-03-31       Impact factor: 3.787

3.  Prediction of lower-grade glioma molecular subtypes using deep learning.

Authors:  Yutaka Matsui; Takashi Maruyama; Masayuki Nitta; Taiichi Saito; Shunsuke Tsuzuki; Manabu Tamura; Kaori Kusuda; Yasukazu Fukuya; Hidetsugu Asano; Takakazu Kawamata; Ken Masamune; Yoshihiro Muragaki
Journal:  J Neurooncol       Date:  2019-12-21       Impact factor: 4.130

4.  Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.

Authors:  Yao Yu; Javier Villanueva-Meyer; Matthew R Grimmer; Stephanie Hilz; David A Solomon; Serah Choi; Michael Wahl; Tali Mazor; Chibo Hong; Anny Shai; Joanna J Phillips; Bruce H Wainer; Michael McDermott; Daphne Haas-Kogan; Jennie W Taylor; Nicholas Butowski; Jennifer L Clarke; Mitchel S Berger; Annette M Molinaro; Susan M Chang; Joseph F Costello; Nancy Ann Oberheim Bush
Journal:  Neuro Oncol       Date:  2021-11-02       Impact factor: 13.029

5.  Cognitive Functions in Repeated Glioma Surgery.

Authors:  Gabriele Capo; Miran Skrap; Ilaria Guarracino; Miriam Isola; Claudio Battistella; Tamara Ius; Barbara Tomasino
Journal:  Cancers (Basel)       Date:  2020-04-26       Impact factor: 6.639

6.  Characterizing the Genomic Landscape of Brain Glioma With Circulating Tumor DNA From Tumor In Situ Fluid.

Authors:  Zhiyuan Sheng; Jinliang Yu; Kaiyuan Deng; Hugo Andrade-Barazarte; Ajmal Zemmar; Sijia Li; Nianxuan Li; Zhaoyue Yan; Zhongcan Chen; Yong Sun; Juha Hernesniemi; Xingyao Bu
Journal:  Front Oncol       Date:  2021-03-31       Impact factor: 6.244

Review 7.  Management and outcomes of low-grade gliomas in Africa: A scoping review.

Authors:  Setthasorn Zhi Yang Ooi; Rosaline de Koning; Abdullah Egiz; David Ulrich Dalle; Moussa Denou; Marvin Richie Dongmo Tsopmene; Mehdi Khan; Régis Takoukam; Jay Kotecha; Dawin Sichimba; Yao Christian Hugues Dokponou; Ulrick Sidney Kanmounye; Nourou Dine Adeniran Bankole
Journal:  Ann Med Surg (Lond)       Date:  2022-01-11

8.  Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma.

Authors:  Michael Naidoo; Leanne Jones; Benjamin Conboy; Wael Hamarneh; Darwin D'Souza; Karen Anthony; Lee R Machado
Journal:  Sci Rep       Date:  2022-02-25       Impact factor: 4.379

Review 9.  Systematic review-Time to malignant transformation in low-grade gliomas: Predicting a catastrophic event with clinical, neuroimaging, and molecular markers.

Authors:  Zabina Satar; Gary Hotton; George Samandouras
Journal:  Neurooncol Adv       Date:  2021-07-27

Review 10.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.